Related references
Note: Only part of the references are listed.Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.
Tara Elisabeth Seery et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells
Jay Friedman et al.
ORAL ONCOLOGY (2019)
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Jacob H. Rasmussen et al.
BRITISH JOURNAL OF CANCER (2019)
How patients with an intact immune system develop head and neck cancer
Sarah Greene et al.
ORAL ONCOLOGY (2019)
Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing
Tiziano Ingegnere et al.
FRONTIERS IN IMMUNOLOGY (2019)
T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
Stacey L. Doran et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Lillian Sun et al.
JCI INSIGHT (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Rohtesh S. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2018)
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
Jay Friedman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy
Lillian Sun et al.
ONCOIMMUNOLOGY (2018)
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies
Paulina Nowakowska et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
Sean P. Arlauckas et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Janet Lau et al.
NATURE COMMUNICATIONS (2017)
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Brent A. Williams et al.
ONCOTARGET (2017)
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells
Paul E. Clavijo et al.
ONCOTARGET (2017)
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Takuro Noguchi et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma
Colin W. Steele et al.
CANCER CELL (2016)
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao et al.
CELL (2016)
Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies
Sujay Shah et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
Caroline Jochems et al.
ONCOTARGET (2016)
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
Xilin Chen et al.
ONCOTARGET (2016)
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
Luc G. T. Morris et al.
ONCOTARGET (2016)
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients
Thomas Condamine et al.
SCIENCE IMMUNOLOGY (2016)
A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease
Michael D. Onken et al.
CLINICAL CANCER RESEARCH (2014)
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
Antje Sucker et al.
CLINICAL CANCER RESEARCH (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
Nancy P. Judd et al.
CANCER RESEARCH (2012)
NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects
Janelle A. Olson et al.
BLOOD (2010)
GENOTYPING OF 73 UM-SCC HEAD AND NECK SQUAMOUS CELL CARCINOMA CELL LINES
J. Chad Brenner et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2010)
Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-beta 1
Hequan Li et al.
JOURNAL OF IMMUNOLOGY (2009)
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
JS Miller et al.
BLOOD (2005)
Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92
G Maki et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Share Paper
